Experimental drug shows promise in rare melanoma subtype
Disease control
Completed
This study tested an experimental drug called PLX3397 in 6 people with advanced melanoma that has a specific change in the KIT gene. The goal was to see if the drug is safe and can shrink tumors. While some patients had their tumors shrink or stay stable, the study was very small…
Phase: NA • Sponsor: Daiichi Sankyo Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:39 UTC